

SAFETY DATA SHEET



GlaxoSmithKline

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Material	MAXIMUM STRENGTH CONTAC COLD AND FLU CAPLETS
Synonyms	CONTAC DAY & NIGHT COLD & FLU CAPLETS - NIGHT FORMULA * MAXIMUM STRENGTH CONTAC COLD AND FLU CAPLETS * PROJECT FILAMENT * FORMULA NUMBER 223 * PARACETAMOL, CHLORPHENIRAMINE MALEATE AND PHENYLEPHRINE HYDROCHLORIDE, FORMULATED PRODUCT
Company Name	GlaxoSmithKline, Corporate Environment, Health & Safety 980 Great West Road Brentford, Middlesex TW8 9GS UK UK General Information: +44-20-8047-5000 Transport Emergency (EU) +44-1865-407333 Medical Emergency +1-612-221-3999, Ext 221 Information and Advice: US number, available 24 hours Multi-language response GlaxoSmithKline, Corporate Environment, Health & Safety One Franklin Plaza, 200 N 16th Street Philadelphia, PA 19102-1225 US US General Information: +1-888-825-5249 Transport Emergency (non EU) +1-703-527-3887 US number, available 24 hours Multi-language response

2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients	CAS RN	Percentage
PARACETAMOL	103-90-2	74.3
CHLORPHENIRAMINE MALEATE	113-92-8	0.3
PHENYLEPHRINE HYDROCHLORIDE	61-76-7	0.74
NON-HAZARDOUS INGREDIENTS	Unassigned	24.66

3. HAZARDS IDENTIFICATION

Fire and Explosion	Expected to be non-combustible.
* Health	Exposure might occur via ingestion; skin; eyes. Health effects information is based on hazards of components.
* Environment	Harmful to aquatic organisms.

4. FIRST-AID MEASURES

Ingestion	Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.
Inhalation	Physical form suggests that risk of inhalation exposure is negligible.
Skin Contact	Using appropriate personal protective equipment, remove contaminated clothing and flush exposed area with large amounts of water. Obtain medical attention if skin reaction occurs, which may be immediate or delayed.
Eye Contact	Wash immediately with clean and gently flowing water. Continue for at least 15 minutes. Obtain medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment	Medical treatment in cases of overexposure should be treated as an overdose of acetaminophen/paracetamol. Treat according to locally accepted protocols. For additional guidance, refer to the local poison control information centre.
Medical Conditions Caused or Aggravated by Exposure	None for occupational exposure.
Antidotes	No specific antidotes are recommended.

5. FIRE-FIGHTING MEASURES

Fire and Explosion Hazards	Not expected for the product, although the packaging is combustible.
Extinguishing Media	Water or foam extinguishers are recommended. Carbon dioxide or dry powder extinguishers may be ineffective.
Special Firefighting Procedures	For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapours might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters. If possible, contain and collect firefighting water for later disposal.
Hazardous Combustion Products	Toxic, corrosive or flammable thermal decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions	Wear protective clothing and equipment consistent with the degree of hazard.
Environmental Precautions	For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.
Clean-up Methods	Collect and place it in a suitable, properly labelled container for recovery or disposal.
Decontamination Procedures	No specific decontamination or detoxification procedures have been identified for this product.

7. HANDLING AND STORAGE**HANDLING**

General Requirements Avoid breaking or crushing tablets.

STORAGE

No storage requirements necessary for occupational hazards. Follow product information storage instructions to maintain efficacy.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

INGREDIENT	PARACETAMOL
GSK Occupational Hazard Category	1
GSK Occupational Exposure Limit	4000 MCG/M3 (8 HR TWA)
INGREDIENT	CHLORPHENIRAMINE MALEATE
GSK Occupational Hazard Category	4
GSK Occupational Exposure Limit	10 MCG/M3 (8 HR TWA)
INGREDIENT	PHENYLEPHRINE HYDROCHLORIDE
GSK Occupational Hazard Category	3
GSK Occupational Exposure Limit	30 mcg/m3 (8 HR TWA) 200 mcg/m3 (15 MIN STEL)

PERSONAL PROTECTIVE EQUIPMENT

Eye Protection	Wear approved safety glasses with side shields if eye contact is possible.
Other Equipment or Procedures	An eye wash station should be available. Wash hands and arms thoroughly after handling.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	
Colour	Yellow.
Physical Form	Tablet.

10. STABILITY AND REACTIVITY

Stability	This product is expected to be stable.
Conditions to Avoid	None for normal handling of this product.

11. TOXICOLOGICAL INFORMATION

Oral Toxicity	Not expected to be toxic following ingestion.
Inhalation Toxicity	No studies have been conducted.
Skin Effects	Irritation is not expected following direct contact.
Eye Effects	Minor irritation might occur following direct contact with eyes.
Target Organ Effects	Adverse effects might occur in the following organ(s) following overexposure: liver.
Sensitisation	Sensitisation (allergic skin reaction) is not expected.
Genetic Toxicity	Not expected to be genotoxic under occupational exposure conditions.
Carcinogenicity	Not expected to produce cancer in humans under occupational exposure conditions. No components are listed as carcinogens by GSK, IARC, NTP or US OSHA.
Reproductive Effects	No adverse effects have been reported following extensive use or exposure in humans.
Other Adverse Effects	None known for occupational exposure.

12. ECOLOGICAL INFORMATION

Summary This product contains an active ingredient that has been tested and which may be harmful if released directly to the environment. Appropriate precautions should be taken to limit release of this material to the environment. Local regulations and procedures should be consulted prior to environmental release.

ECOTOXICITY

Aquatic

Daphnid This mixture contains a major component(s) that is toxic to daphnids.

13. DISPOSAL CONSIDERATIONS

Disposal Recommendations Collect for recycling or recovery if possible. The disposal method for rejected products/returned goods must ensure that they cannot be re-sold or re-used.

Regulatory Requirements Observe all local and national regulations when disposing of this product.

14. TRANSPORT INFORMATION

The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport.

UN Classification and Labelling

Transport Information Transportation and shipping of this product is not restricted. It has no known, significant hazards requiring special packaging or labelling for air, maritime, US or European ground transport purposes.

15. REGULATORY INFORMATION

The information included below is an overview of the major regulatory requirements. It should not be considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.

EU Classification and Labelling

Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product, cosmetic product or medical device.

US OSHA Standard (29 CFR Part 1910.1200)

Classification Exempt when packaged for sale to consumers in a retail establishment.

Other US Regulations

TSCA Status Exempt

16. OTHER INFORMATION

References GSK Hazard Determination

Date Approved/Revised 13-Dec-2006

SDS Version Number 4

SDS Sections Updated

Sections

HAZARDS IDENTIFICATION

Subsections

Conditions Aggravated by Exposure

Environment

Eye Contact

Health

Ingestion

Inhalation

SDS Sections Updated**Sections**

HAZARDS IDENTIFICATION

Subsections

Overview

Skin Contact

Summary

IDENTIFICATION OF SUBSTANCE / PREPARATION AND
OF COMPANY

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.